iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

OTC Drug Regulation on the Table

17 Dec 2024 , 10:34 AM

To resolve concerns about over-the-counter (OTC) medications, government representatives, international pharmaceutical corporations, and pharma lobby groups will convene on Tuesday.

Medications that are offered directly to consumers without a prescription are known as over-the-counter (OTC) medications. Pain, colds and coughs, diarrhea, constipation, acne, and other ailments are all treated with over-the-counter medications. Certain over-the-counter medications contain active components that can be abused at dosages higher than advised.

In 2023, American consumers spent nearly $43 billion on over-the-counter medications, according to Euromonitor International. By doing this, customers gained the ability to treat a variety of common ailments on their own.

“When OTC medications are used appropriately, they increase accessibility and cost for the treatment and prevention of common ailments. OTC medications have many advantages, but they also come with a number of drawbacks. Therefore, the brainstorming session between government officials, pharmaceutical lobby organizations, and the sector is crucial,” a senior insider stated to ET.

According to news reports, the drug regulator established an expert group earlier this year to assess medications that could be made over-the-counter (OTC) after pharmaceutical companies requested that their products be made so.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • GOI
  • Government
  • India
  • OTC Drugs
  • Pharma
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.